Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan
2011

Extended-Dose Chloroquine for Malaria Treatment in Afghan Refugees

Sample size: 142 publication 10 minutes Evidence: high

Author Information

Author(s): Howard Natasha, Durrani Naeem, Sanda Sanda, Beshir Khalid, Hallett Rachel, Rowland Mark

Primary Institution: London School of Hygiene and Tropical Medicine (LSHTM)

Hypothesis

Is a five-day treatment of chloroquine more effective than a three-day treatment for curing falciparum malaria in Afghan refugees?

Conclusion

The extended-dose chloroquine regimen can overcome some resistant infections, but its high failure rate makes it unsuitable for first-line treatment.

Supporting Evidence

  • 84% of CQ25 patients experienced recrudescence compared to 51% of CQ40 patients.
  • Cure rates were significantly improved with CQ40, particularly among adults.
  • The study found high failure rates for CQ40 when used as second-line treatment.

Takeaway

This study tested two different lengths of malaria treatment for Afghan refugees. The longer treatment worked better, but still didn't cure enough people.

Methodology

A randomized controlled trial comparing two treatment regimens (CQ25 and CQ40) with follow-up for 60 days.

Potential Biases

Potential bias in patient selection and follow-up due to the nature of refugee health care.

Limitations

The study did not measure adherence to treatment, which could affect outcomes.

Participant Demographics

Participants were Afghan refugees with uncomplicated falciparum malaria, aged 0-15 years.

Statistical Information

P-Value

< 0.05

Confidence Interval

95%CI 0.08-0.38

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-2875-10-171

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication